Clinical trials of oral therapeutics for COVID-19 patients will take place at Riverside
Riverside University Health System Medical Center, along with Skymount Medical and Louisiana State University, will conduct clinical trials on the efficacy of oral therapeutics for COVID-19 patients, according to a press release.
The testing is part of a newly-approved outpatient study that will take place at RUHS Medical Center’s Comparative Effectiveness & Clinical Outcomes Research Center in Moreno Valley. A press release states it will evaluate the “combined effects of an already FDA-approved cancer medication and an already FDA-approved anti-parasitic agent” on patients with mild-to-moderate COVID-19 infection who do not require hospitalization.
Predictive studies from LSU’s artificial intelligence technology and preclinical cell and animal research show the two-drug combination is up to 97% effective in reducing the concentration of the SARS-CoV-2 virus, a press release states.
The study will be a double-blind intervention done in an outpatient setting, which will compare the two-drug combination to a placebo, according to a press release. The goal is to see the combination therapy’s impact on decreasing the length and severity of symptoms without negative side effects. The study will also determine if the combination drug can help decrease a patient’s need to be hospitalized.
Patients with COVID-19 are welcome to participate in the study.
“Unfortunately, California has its fair share of COVID-19 cases,” said Dr. Bruce Weng, RUHS Medical Center Infectious Disease physician, in a statement. “The one silver lining in this is that the sample size at our hospital is substantial enough to produce valuable data when evaluating the safety and efficacy of this drug combination.”
Participation in the study is voluntary. Weng added that researchers will ” stay in constant contact” with participants to “ensure their health and well-being.”
Some individuals have experienced COVID long-haul and their symptoms persist several months after their initial diagnosis. There’s hope the combination treatment could offer help.
Similar studies are currently taking place in Europe. If the treatment receives final approval, Skymount Medical intends to make it widely available and cost-effective, according to a press release.
Ema Sasic covers health in the Coachella Valley. Reach her at firstname.lastname@example.org or on Twitter @ema_sasic.